HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity.

Abstract
Chemotherapy of leishmaniasis is mainly based on antimonials. However, they are extremely toxic and cause serious side effects, and there is a worldwide increasing frequency of chemoresistance to antimonials. These issues emphasize the urgent need for affordable alternative drugs against leishmaniasis. Leishmania cysteine proteases are essential for parasite growth, differentiation, pathogenicity, and virulence and are thus attractive targets for combating leishmaniasis. Herein we demonstrate that the cysteine protease inhibitors aziridine-2,3-dicarboxylates 13b and 13e impaired promastigote growth at mid-micromolar concentrations and decreased the infection rate of peritoneal macrophages at concentrations 8- to 13-fold lower than those needed to inhibit parasite replication. Simultaneous treatment of infected cells with compound 13b and gamma interferon resulted in an even further reduction of the concentration needed for a significant decrease in macrophage infection rate. Notably, treatment with the compounds alone modulated the cytokine secretion of infected macrophages, with increased levels of interleukin-12 and tumor necrosis factor alpha. Furthermore, the decreased infection rate in the presence of compound 13b correlated with increased nitric oxide production by macrophages. Importantly, at the concentrations used herein, compounds 13b and 13e were not toxic against fibroblasts, macrophages, or dendritic cells. Together, these results suggest that the aziridine-2,3-dicarboxylates 13b and 13e are potential antileishmanial lead compounds with low toxicity against host cells and selective antiparasitic effects.
AuthorsAlicia Ponte-Sucre, Radim Vicik, Martina Schultheis, Tanja Schirmeister, Heidrun Moll
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 50 Issue 7 Pg. 2439-47 (Jul 2006) ISSN: 0066-4804 [Print] United States
PMID16801424 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiprotozoal Agents
  • Aziridines
  • Cysteine Proteinase Inhibitors
  • Cytokines
  • aziridine-2,3-dicarboxylate
Topics
  • Animals
  • Antiprotozoal Agents (chemistry, pharmacology, toxicity)
  • Aziridines (chemistry, pharmacology, toxicity)
  • Bone Marrow Cells
  • Cell Line
  • Cells, Cultured
  • Cysteine Proteinase Inhibitors (chemistry, pharmacology, toxicity)
  • Cytokines (metabolism)
  • Dendritic Cells (parasitology)
  • Leishmania major (drug effects, growth & development)
  • Macrophages, Peritoneal (drug effects, immunology, parasitology)
  • Mice
  • Mice, Inbred BALB C
  • NIH 3T3 Cells

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: